Most cancers were RAS or BRAF wild-type in all cohorts (97.7% and 98.8%, respectively); in cohort A, 1 patient’s tumor had an NRAS mutation, 1 patient’s tumor in cohort B was not examined for RAS, and 1 patient’s tumor in cohort C was not examined for BRAF. Liver metastasis at baseline was present in 66.3% of patients (Table 2). This evidence concerns the gene NRAS and cancer.